Clinical-stage immuno-oncology company, Surface Oncology, Inc. is making waves in the US cancer drug development scene with its range of innovative cancer therapies. The company's portfolio of antibodies includes NZV930 and SRF617, both fully human immunoglobulin isotype G4 monoclonal antibodies which regulate the production and breakdown of adenosine, and SRF388, currently in phase II clinical trials targeting interleukin 27. Additionally, GSK4381562 is an antibody targeting CD112R, while SRF114 is in phase 1/2 clinical trials targeting chemokine receptor CCR8. Notably, Surface Oncology, Inc. has partnered with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. for the development, manufacture, and commercialization of SRF114 antibodies. Established in 2014 and headquartered in Cambridge, Massachusetts, Surface Oncology, Inc. is a company to watch in the immuno-oncology space.